Escalating Cost Pressures Move Back to the Forefront

U.S. healthcare spending continues to rise faster than wages and general inflation, and the latest wave of policy analysis and state-level reforms underscores how that trajectory is reshaping the financial outlook for insurers, providers, and patients.

National per capita healthcare spending growth remains elevated, with recent discussion from policy experts at Rutgers University’s Bloustein School highlighting how rising costs are weighing particularly heavily on people with private insurance. In their recent analysis of New Jersey Governor Mikie Sherrill’s healthcare proposals, Professors Joel Cantor and Derek DeLia emphasized that nationally, per capita healthcare spending continues to grow rapidly and that privately insured households are feeling the steepest increases in premiums and out-of-pocket expenses.

Concurrently, employers and health plans are sounding the alarm over the durability of these trends. Insights recapped by Merative from its recent Truven Summit point to employers struggling with “rising healthcare spend, persistent pharmacy challenges, and growing concern about how to keep benefits affordable for employees.” These concerns are mirrored in human-resources–focused briefings, including sessions like North Risk Partners’ “Today’s HR Reality,” which frame healthcare cost escalation as a central strategic risk for corporate benefits budgets.

The cost problem is no longer abstract. It is directly influencing reimbursement policies, regulatory scrutiny of pricing, and the pace at which payers and providers adopt digital and AI-enabled solutions to manage utilization and shift toward value-based care.

Policy and Regulatory Front: Cost Control Moves Center Stage

At the policy level, the most concrete developments in the last day revolve around state and federal efforts to manage cost growth and increase transparency, rather than across-the-board spending cuts.

In New Jersey, Governor Sherrill’s health proposals—analyzed by Cantor and DeLia—maintain or modestly increase funding for the state’s healthcare safety net, including NJ FamilyCare (Medicaid), the Cover All Kids initiative, Federally Qualified Health Centers, and hospital charity care for the uninsured. Crucially for cost dynamics, the plan continues to support the Office of Health Care Affordability and Transparency (OHCAT), which operates the Health Care Affordability, Responsibility, and Transparency (HART) program.

HART sets explicit targets for healthcare spending growth statewide, effectively functioning as a soft cap or benchmark similar to global budgets and cost-growth targets used in other states. For insurers and hospitals operating in New Jersey, these targets create long-term pressure to control utilization, limit price increases, and justify any deviation from benchmark growth rates with demonstrable value improvements.

At the national level, Congress is again debating stronger price transparency requirements. As highlighted by a recent Mercer briefing, lawmakers are weighing proposals to tighten hospital price transparency rules by requiring actual dollar-and-cents prices for posted rates—rather than estimates—and by stepping up enforcement. Additional measures would push more transparency around health plan pricing and third‑party payment arrangements.

These transparency initiatives are not directly capping prices, but for hospital operators, pharmacy benefit managers (PBMs), and some insurers, they raise the risk of margin compression over time as employers and regulators gain clearer line-of-sight into negotiated rates and spread-based revenue.

Pharmacy Economics: Pennsylvania’s Act 77 Study Highlights Margin Reallocation

One of the most detailed, data-driven developments to emerge recently is the Pennsylvania Insurance Department’s Act 77 of 2024 Impact Study, which assesses changes to prescription drug reimbursement structures in the state’s insurance market.

The report examines a shift toward reimbursing pharmacies based on the National Average Drug Acquisition Cost (NADAC) plus a fixed dispensing fee of $10.49. The analysis finds that moving to NADAC plus a $10.49 dispensing fee would keep total prescription drug spending in the Commonwealth’s insurance markets broadly flat, with an increase of less than 0.5% relative to current levels. In dollar terms, the report estimates that the difference between current reimbursement levels and the NADAC plus $10.49 approach would be around $36.8 million in 2024.

Importantly, the study concludes that most of this impact represents a redistribution of reimbursement—away from some segments and toward others—rather than a major change in total system cost. Independent retail pharmacies would generally receive higher reimbursement, strengthening their financial position, while PBMs and some insurers could see reduced spread and margin on certain pharmacy transactions.

The report also models a scenario where the $10.49 dispensing fee applies only to independent retail pharmacies. Under that design, the total cost of prescription drugs in Pennsylvania’s insurance market would increase by approximately $14 million, equivalent to about 0.3% of total prescription drug spending. Again, the key effect is targeted: strengthening independent pharmacy economics while producing only a modest system-wide cost increase.

For public PBM operators and managed-care organizations with exposure to Pennsylvania and other states considering similar structures, this type of reform implies incremental margin pressure on traditional spread-based pharmacy revenue, while potentially creating opportunities to differentiate through transparent, pass‑through models and integrated pharmacy-and-medical management.

Impact on Insurers and Managed Care: Margin Pressure Meets Tech Enablement

For investors in health insurers and managed-care organizations, escalating healthcare costs and related policy responses translate into a complex mix of risks and opportunities.

Margin pressure from medical cost trend. As Cantor and DeLia note, privately insured populations are facing particularly steep cost increases. For commercial insurers and self-funded employer plans, this manifests as higher medical loss ratios (MLRs) if premium rates fail to fully anticipate rising hospital, physician, and drug costs. With states like New Jersey implementing cost‑growth benchmarks, regulators may be less tolerant of large premium hikes, tightening the range within which insurers can pass through higher medical trend.

Regulatory risk from transparency and pharmacy reforms. The Pennsylvania Act 77 analysis shows how state-level pharmacy reforms can be structured to protect independents and beneficiaries with only modest total-cost impact—but at the expense of some PBM margins. Coupled with federal interest in greater transparency, PBMs embedded within large insurers could face incremental regulatory and pricing risk. Over time, that may favor scale players who can pivot to lower‑spread, service-fee–driven models while leveraging data analytics to manage total cost of care.

Tailwinds for value‑based and tech‑enabled models. At the same time, these cost constraints are strengthening the business case for digital care management, telehealth, and AI-enabled analytics. Managed-care plans are increasingly incentivized to invest in tools that reduce avoidable hospitalizations, optimize site-of-care, and manage pharmacy utilization—especially in high-cost segments like oncology, where a recent ASCO-published analysis notes a rise in utilization management techniques by commercial health plans.

Publicly traded insurers with strong technology platforms and value‑based care partnerships stand to benefit relative to peers. Their ability to bend trend closer to benchmarks such as New Jersey’s HART targets or employer cost-growth expectations becomes a competitive advantage when negotiating premiums and maintaining margins.

Hospitals and Health Systems: Revenue Growth Versus Cost Growth

Hospital operators are on the other side of the same equation. Rising wage costs, expensive specialty drugs, and capital expenditure needs are pushing health systems to seek higher commercial reimbursement and more predictable funding streams. New Jersey’s proposals to maintain or modestly increase support for Medicaid, charity care, and Federally Qualified Health Centers provide some relief for safety‑net institutions. However, statewide cost‑growth targets limit the ability of hospitals to rely on annual above-trend price increases.

For publicly traded hospital companies, the policy signal is clear: volume and mix, not unit price, will drive incremental revenue growth. That dynamic incentivizes investment in ambulatory and outpatient care, partnerships with Medicare Advantage and Medicaid managed-care plans, and participation in risk‑bearing value-based contracts. It also increases appetite for digital tools that can improve throughput, reduce length of stay, and manage capacity more efficiently.

Investors should expect continued divergence between health systems that can integrate digital care pathways, leverage data for population health management, and navigate value-based models, and those that remain reliant on fee-for-service inpatient volume. Policy structures like New Jersey’s HART program will accelerate that divergence.

Digital Health and AI: Cost Crisis as a Catalyst

For digital health companies, the persistent cost crisis is a structural tailwind, even as near-term funding markets remain selective. Employers and health plans, as described in the Merative Truven Summit recap, are under intensifying pressure to keep benefits affordable amid rising healthcare and pharmacy spend. That lends support to solutions that demonstrate clear, measurable impact on total cost of care and employee productivity.

Care management and analytics. Platforms that use AI and advanced analytics to identify high-risk members, improve medication adherence, and close care gaps align squarely with insurers’ and employers’ need to control trend. As pharmacy reforms like Pennsylvania’s Act 77 emphasize the importance of cost-accurate data (e.g., NADAC-based pricing) and transparent reimbursement, analytic vendors that can integrate pharmacy and medical data into a single view are well positioned to capture share.

Telehealth and virtual primary care. While utilization of broad, on-demand telehealth has normalized post-pandemic, virtual primary care, behavioral health, and chronic-disease management remain attractive areas. They can be priced as predictable per‑member‑per‑month services and, when integrated with plan benefits, can divert members from more expensive emergency and inpatient settings. In a world of state-level cost-growth caps and aggressive employer procurement, digital health vendors that can produce outcomes validated by claims data will hold a defensible edge.

Oncology and specialty care solutions. The ASCO Journal’s recent review of oncology utilization management trends underscores growing payer scrutiny on high-cost specialty drugs and regimens. Digital platforms that support evidence-based treatment pathways, prior authorization automation, and outcomes tracking in oncology can tap into a large and growing spend category under intense payer pressure.

From a market perspective, the likely beneficiaries are scale digital health platforms integrated with health plans and large self‑funded employers, along with niche players focused on high‑cost conditions. Companies overly reliant on direct‑to‑consumer cash-pay models may find growth more challenged as household budgets strain under rising premiums and out‑of‑pocket costs.

Medicaid, Medicare, and Coverage Expansion: Volume Tailwinds, Pricing Constraints

Public coverage policies remain a critical backdrop. According to the latest data compiled by KFF, 41 states plus the District of Columbia have adopted the Affordable Care Act’s Medicaid expansion, while 10 states have not. The ACA expansion extends Medicaid to nearly all adults with incomes up to 138% of the Federal Poverty Level, defined as $21,597 for an individual in 2025.

For managed-care organizations with Medicaid and Medicare Advantage exposure, expanded coverage supports enrollment growth and more stable premium funding. New Jersey’s commitment to NJ FamilyCare and programs like Cover All Kids (which covers children regardless of immigration status) adds further volume stability in that state. However, public programs typically reimburse at lower rates than commercial insurance, reinforcing the need to manage medical costs aggressively.

Digital health solutions that can scale into Medicaid and Medicare populations—where chronic disease burden is high and social determinants of health play a major role—stand to benefit from this coverage landscape. Investors should pay particular attention to companies that can operate within the constraints of public program reimbursement while demonstrating reductions in hospital utilization and improved quality scores.

Investment Implications Across the Healthcare Stack

In aggregate, the latest developments around U.S. healthcare cost escalation, state-level reforms, and transparency efforts point to several medium‑term themes for investors:

• Managed-care leaders with strong tech and analytics are positioned to outperform as they deploy digital tools to manage trend within regulatory cost-growth targets and satisfy employer demands.

• PBMs and pharmacy‑linked insurers face incremental policy risk, as Pennsylvania’s Act 77 analysis and similar efforts signal a shift toward more transparent, acquisition‑cost–based reimbursement structures that redistribute margins toward pharmacies.

• Hospitals and health systems will see constraints on unit price increases in states adopting cost‑growth benchmarks, making operational efficiency and digital transformation critical drivers of equity value.

• Digital health and AI platforms that can prove cost-savings and outcomes improvements are structural beneficiaries of payer and employer cost pressure, particularly in chronic disease, behavioral health, and oncology.

• Medicaid and Medicare policy stability provides volume support, but margins remain capped, reinforcing the importance of scalable, low-cost care models infused with digital capabilities.

Conclusion: Cost Pressure as a Long-Term Structural Theme

The re‑emergence of healthcare costs as a top-tier policy and corporate concern is not a transient phenomenon. Recent analyses—from New Jersey’s affordability initiatives to Pennsylvania’s Act 77 pharmacy impact study and federal discussions on transparency—highlight a policy architecture that accepts high baseline spending but seeks to constrain future growth and reallocate margins more equitably across the system.

For equity investors, this environment is challenging but investable. Traditional pricing power is likely to erode gradually for hospitals and PBMs, while insurers face tighter regulatory guardrails around premium growth and medical loss ratios. At the same time, the pressure to deliver more care for every healthcare dollar is creating enduring demand for digital health, AI-driven analytics, and value-based care platforms.

Positioning portfolios to favor managed-care organizations with advanced technology capabilities, hospital operators committed to digital transformation, and proven cost‑reducing digital health vendors offers a way to align with the underlying policy and economic currents. As cost containment and transparency move from rhetoric to implementation, differentiation will increasingly hinge on the ability to turn data and digital tools into tangible reductions in total cost of care—an area where the most sophisticated health and technology players are poised to lead.